Search

Your search keyword '"Carter,Victoria"' showing total 731 results
Start Over Author "Carter,Victoria"
731 results on '"Carter,Victoria"'

2. The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia

Author

Price, David, Jenkins, Christine, Hancock, Kerry, Vella, Rebecca, Heraud, Florian, Le Cheng, Porsche, Murray, Ruth, Beekman, Maarten, Bosnic-Anticevich, Sinthia, Botini, Fabio, Carter, Victoria, Catanzariti, Angelina, Doan, Joe, Fletton, Kirsty, Kichkin, Ata, Le, Thao, Le Lievre, Chantal, Lau, Chi Ming, Novic, Dominique, Pakos, John, Ranasinghe, Kanchanamala, Roussos, Alexander, Samuel-King, Josephine, Sharma, Anita, Stewart, Deb, Willet, Bruce, and Bateman, Eric

Published
2024
Full Text
View/download PDF

3. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma

Author

Scelo, Ghislaine, Tran, Trung N., Le, Tham T., Fagerås, Malin, Dorscheid, Delbert, Busby, John, Al-Ahmad, Mona, Al-Lehebi, Riyad, Altraja, Alan, Beastall, Aaron, Bergeron, Celine, Bjermer, Leif, Bjerrum, Anne S., Cano-Rosales, Diana Jimena, Canonica, Giorgio Walter, Carter, Victoria, Charriot, Jeremy, Christoff, George C., Cosio, Borja G., Denton, Eve, Fernandez-Sanchez, Maria Jose, Fonseca, João A., Gibson, Peter G., Goh, Celine, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Iwanaga, Takashi, Katial, Rohit, Koh, Mariko S., Kuna, Piotr, Larenas-Linnemann, Désirée, Lehtimäki, Lauri, Mahboub, Bassam, Martin, Neil, Matsumoto, Hisako, Menzies-Gow, Andrew N., Papadopoulos, Nikolaos G., Patel, Pujan, Perez-De-Llano, Luis, Peters, Matthew, Pfeffer, Paul E., Popov, Todor A., Porsbjerg, Celeste M., Rhee, Chin K., Sadatsafavi, Mohsen, Taillé, Camille, Torres-Duque, Carlos A., Tsai, Ming-Ju, Ulrik, Charlotte S., Upham, John W., von Bülow, Anna, Wang, Eileen, Wechsler, Michael E., and Price, David B.

Published
2024
Full Text
View/download PDF

4. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

Author

Perez-de-Llano, Luis, Scelo, Ghislaine, Canonica, G. Walter, Chen, Wenjia, Henley, William, Larenas-Linnemann, Désirée, Peters, Matthew J., Pfeffer, Paul E., Tran, Trung N., Ulrik, Charlotte Suppli, Popov, Todor A., Sadatsafavi, Mohsen, Hew, Mark, Máspero, Jorge, Gibson, Peter G., Christoff, George C., Fitzgerald, J. Mark, Torres-Duque, Carlos A., Porsbjerg, Celeste M., Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Heffler, Enrico, Iwanaga, Takashi, Al-Ahmad, Mona, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Rhee, Chin Kook, Koh, Mariko Siyue, Cosio, Borja G., Perng (Steve), Diahn-Warng, Mahboub, Bassam, Menzies-Gow, Andrew N., Jackson, David J., Busby, John, Heaney, Liam G., Patel, Pujan H., Wang, Eileen, Wechsler, Michael E., Altraja, Alan, Lehtimäki, Lauri, Bourdin, Arnaud, Bjermer, Leif, Bulathsinhala, Lakmini, Carter, Victoria, Murray, Ruth, Beastall, Aaron, Denton, Eve, and Price, David B.

Published
2024
Full Text
View/download PDF

6. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry

Author

Scelo, Ghislaine, Torres-Duque, Carlos A., Maspero, Jorge, Tran, Trung N., Murray, Ruth, Martin, Neil, Menzies-Gow, Andrew N., Hew, Mark, Peters, Matthew J., Gibson, Peter G., Christoff, George C., Popov, Todor A., Côté, Andréanne, Bergeron, Celine, Dorscheid, Delbert, FitzGerald, J. Mark, Chapman, Kenneth R., Boulet, Louis Philippe, Bhutani, Mohit, Sadatsafavi, Mohsen, Jiménez-Maldonado, Libardo, Duran-Silva, Mauricio, Rodriguez, Bellanid, Celis-Preciado, Carlos Andres, Cano-Rosales, Diana Jimena, Solarte, Ivan, Fernandez-Sanchez, Maria Jose, Parada-Tovar, Patricia, von Bülow, Anna, Bjerrum, Anne Sofie, Ulrik, Charlotte S., Assing, Karin Dahl, Rasmussen, Linda Makowska, Hansen, Susanne, Altraja, Alan, Bourdin, Arnaud, Taille, Camille, Charriot, Jeremy, Roche, Nicolas, Papaioannou, Andriana I., Kostikas, Konstantinos, Papadopoulos, Nikolaos G., Salvi, Sundeep, Long, Deirdre, Mitchell, Patrick D., Costello, Richard, Sirena, Concetta, Cardini, Cristina, Heffler, Enrico, Puggioni, Francesca, Canonica, Giorgio Walter, Guida, Giuseppe, Iwanaga, Takashi, Al-Ahmad, Mona, Linnemann, Désirée Larenas, Garcia, Ulises, Kuna, Piotr, Fonseca, João A., Al-Lehebi, Riyad, Koh, Mariko Siyue, Rhee, Chin Kook, Cosio, Borja G., de Llano, Luis Perez, Perng (Steve), Diahn-Warng, Huang, Erick Wan-Chun, Wang, Hao-Chien, Tsai, Ming-Ju, Mahboub, Bassam, Salameh, Laila Ibraheem Jaber, Jackson, David, Busby, John, Heaney, Liam G., Pfeffer, Paul, Goddard, Amanda Grippen, Wang, Eileen, Hoyte, Flavia, Wechsler, Michael E., Chapman, Nicholas, Katial, Rohit, Carter, Victoria, Bulathsinhala, Lakmini, Eleangovan, Neva, Ariti, Con, Lyu, Juntao, Price, David B., and Porsbjerg, Celeste

Published
2024
Full Text
View/download PDF

7. Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

Author

Chen, Wenjia, Tran, Trung N., Sadatsafavi, Mohsen, Murray, Ruth, Wong, Nigel Chong Boon, Ali, Nasloon, Ariti, Con, Bulathsinhala, Lakmini, Gil, Esther Garcia, FitzGerald, J. Mark, Alacqua, Marianna, Al-Ahmad, Mona, Altraja, Alan, Al-Lehebi, Riyad, Bhutani, Mohit, Bjermer, Leif, Bjerrum, Anne-Sofie, Bourdin, Arnaud, von Bülow, Anna, Busby, John, Canonica, Giorgio Walter, Carter, Victoria, Christoff, George C., Cosio, Borja G., Costello, Richard W., Fonseca, João A., Gibson, Peter G., Yoo, Kwang-Ha, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Hilberg, Ole, Hoyte, Flavia, Iwanaga, Takashi, Jackson, David J., Jones, Rupert C., Koh, Mariko Siyue, Kuna, Piotr, Larenas-Linnemann, Désirée, Lehmann, Sverre, Lehtimäki, Lauri, Lyu, Juntao, Mahboub, Bassam, Maspero, Jorge, Menzies-Gow, Andrew N., Newell, Anthony, Sirena, Concetta, Papadopoulos, Nikolaos G., Papaioannou, Andriana I., Perez-de-Llano, Luis, Perng (Steve), Diahn-Warng, Peters, Matthew, Pfeffer, Paul E., Porsbjerg, Celeste M., Popov, Todor A., Rhee, Chin Kook, Salvi, Sundeep, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos A., Ulrik, Charlotte, Ra, Seung-Won, Wang, Eileen, Wechsler, Michael E., and Price, David B.

Published
2023
Full Text
View/download PDF

8. Patterns of care in the management of high-risk COPD in the US (2011–2019): an observational study for the CONQUEST quality improvement program

Author

Kerr, Margee, Tarabichi, Yasir, Evans, Alexander, Mapel, Douglas, Pace, Wilson, Carter, Victoria, Couper, Amy, Drummond, M. Bradley, Feigler, Norbert, Federman, Alex, Gandhi, Hitesh, Hanania, Nicola A., Kaplan, Alan, Kostikas, Konstantinos, Kruszyk, Maja, van Melle, Marije, Müllerová, Hana, Murray, Ruth, Ohar, Jill, Pollack, Michael, Pullen, Rachel, Williams, Dennis, Wisnivesky, Juan, Han, MeiLan K., Meldrum, Catherine, and Price, David

Published
2023
Full Text
View/download PDF

9. Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study

Author

Halpin, David M.G., Dickens, Andrew P., Skinner, Derek, Murray, Ruth, Singh, Mukesh, Hickman, Katherine, Carter, Victoria, Couper, Amy, Evans, Alexander, Pullen, Rachel, Menon, Shruti, Morris, Tamsin, Muellerova, Hana, Bafadhel, Mona, Chalmers, James, Devereux, Graham, Gibson, Martin, Hurst, John R., Jones, Rupert, Kostikas, Konstantinos, Quint, Jennifer, Singh, Dave, van Melle, Marije, Wilkinson, Tom, and Price, David

Published
2023
Full Text
View/download PDF

11. COPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry

Author

Pace, Wilson D., Brandt, Elias, Carter, Victoria A., Chang, Ku-Lang, Edwards, Chelsea L., Evans, Alexander, Fox, Chester, Gaona, Gabriela, Han, MeiLan K., Kaplan, Alan G., Kent, Rachel, Kocks, Janwillem W.H., Kruszyk, Maja, Lievre, Chantal E. Le, Voti, Tessa Li, Mahle, Cathy, Make, Barry, Ratigan, Amanda R., Shaikh, Asif, Skolnik, Neil, Stanley, Brooklyn, Yawn, Barbara P., and Price, David B.

Subjects
Lung diseases, Obstructive -- Demographic aspects -- Drug therapy -- Risk factors, Health, Science and technology
Abstract

PURPOSE To describe demographic and clinical characteristics of chronic obstructive pulmonary disease patients managed in US primary care. METHODS This was an observational registry study using data from the Chronic Obstructive Pulmonary Disease (COPD) Optimum Patient Care DARTNet Research Database from which the Advancing the Patient Experience COPD registry is derived. Registry patients were aged [greater than or equal to]35 years at diagnosis. Electronic health record data were collected from both registries, supplemented with patient-reported information/outcomes from the Advancing the Patient Experience registry from 5 primary care groups in Texas, Ohio, Colorado, New York, and North Carolina (June 2019 through November 2020). RESULTS: Of 17,192 patients included, 1,354 were also in the Advancing the Patient Experience registry. Patients were predominantly female (56%; 9,689/17,192), White (64%; 9,732/15,225), current/ex-smokers (80%; 13,784/17,192), and overweight/obese (69%; 11,628/16,849). The most commonly prescribed maintenance treatments were inhaled corticosteroid with a long-acting [[beta].sub.2]-agonist (30%) and inhaled corticosteroid with a long-acting muscarinic antagonist (27%). Although 3% (565/17,192) of patitents were untreated, 9% (1,587/17,192) were on short-acting bronchodilator monotherapy, and 4% (756/17,192) were on inhaled corticosteroid monotherapy. Despite treatment, 38% (6,579/17,192) of patients experienced 1 or more exacerbations in the last 12 months. These findings were mirrored in the Advancing Patient Experience registry with many patients reporting high or very high impact of disease on their health (43%; 580/1,322), a breathlessness score 2 or more (45%; 588/1,315), and 1 or more exacerbation in the last 12 months (50%; 646/1,294). CONCLUSIONS Our findings highlight the high exacerbation, symptom, and treatment burdens experienced by COPD patients managed in US primary care, and the need for more real-life effectiveness trials to support decision making at the primary care level. Key words: APEX; characterization; electronic medical records; patient reported outcomes; primary care, INTRODUCTION Chronic obstructive pulmonary disease (COPD) represents an important public health challenge that is preventable and treatable. (1) For the 16 million Americans who live with it, COPD carries a [...]

Published
2022
Full Text
View/download PDF

15. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

Author

Porsbjerg, Celeste M., Menzies-Gow, Andrew N., Tran, Trung N., Murray, Ruth B., Unni, Bindhu, Audrey Ang, Shi Ling, Alacqua, Marianna, Al-Ahmad, Mona, Al-Lehebi, Riyad, Altraja, Alan, Belevskiy, Andrey S., Björnsdóttir, Unnur S., Bourdin, Arnaud, Busby, John, Canonica, G. Walter, Christoff, George C., Cosio, Borja G., Costello, Richard W., FitzGerald, J. Mark, Fonseca, João A., Hansen, Susanne, Heaney, Liam G., Heffler, Enrico, Hew, Mark, Iwanaga, Takashi, Jackson, David J., Kocks, Janwillem W.H., Kallieri, Maria, Bruce Ko, Hsin-Kuo, Koh, Mariko Siyue, Larenas-Linnemann, Désirée, Lehtimäki, Lauri A., Loukides, Stelios, Lugogo, Njira, Maspero, Jorge, Papaioannou, Andriana I., Perez-de-Llano, Luis, Pitrez, Paulo Márcio, Popov, Todor A., Rasmussen, Linda M., Rhee, Chin Kook, Sadatsafavi, Mohsen, Schmid, Johannes, Siddiqui, Salman, Taillé, Camille, Taube, Christian, Torres-Duque, Carlos A., Ulrik, Charlotte, Upham, John W., Wang, Eileen, Wechsler, Michael E., Bulathsinhala, Lakmini, Carter, Victoria, Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Rowlands, Mari-Anne, Price, David B., and van Boven, Job F.M.

Published
2022
Full Text
View/download PDF

16. Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults.

Author

Perez-de-Llano, Luis, Scelo, Ghislaine, Tran, Trung N., Le, Tham T., Fagerås, Malin, Cosio, Borja G., Peters, Matthew, Pfeffer, Paul E., Al-Ahmad, Mona, Al-Lehebi, Riyad O., Altraja, Alan, Bergeron, Celine, Bjermer, Leif H., Bjerrum, Anne S., Bulathsinhala, Lakmini, Busby, John, Cano Rosales, Diana J., Canonica, Giorgio W., Carter, Victoria A., and Charriot, Jeremy

Subjects
DISEASE remission, ODDS ratio, ASTHMA, LUNGS, LONGITUDINAL method
Abstract

Rationale: There is no consensus on criteria to include in an asthma remission definition in real life. Factors associated with achieving remission after biologic initiation remain poorly understood. Objectives: To quantify the proportion of adults with severe asthma achieving multidomain-defined remission after biologic initiation and identify prebiologic characteristics associated with achieving remission that may be used to predict it. Methods: This was a longitudinal cohort study using data from 23 countries from the International Severe Asthma Registry. Four asthma outcome domains were assessed in the 1 year before and after biologic initiation. A priori–defined remission cutoffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asthma, and percent predicted FEV1 ⩾ 80%. Remission was defined using two (exacerbations + LTOCS), three (+control or +lung function), and four of these domains. The association between prebiologic characteristics and postbiologic remission was assessed by multivariable analysis. Measurements and Main Results: A total of 50.2%, 33.5%, 25.8%, and 20.3% of patients met criteria for two-, three- (+control), three- (+lung function), and four-domain remission, respectively. The odds of achieving four-domain remission decreased by 15% for every additional 10 years of asthma duration (odds ratio, 0.85; 95% confidence interval, 0.73–1.00). The odds of remission increased in those with fewer exacerbations per year, lower LTOCS daily dose, better control, and better lung function before biologic initiation. Conclusions: One in five patients achieved four-domain remission within 1 year of biologic initiation. Patients with less severe impairment and shorter asthma duration at initiation had a greater chance of achieving remission after biologic treatment, indicating that biologic treatment should not be delayed if remission is the goal. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. A genome-wide cytotoxicity screen of cluster F1 mycobacteriophage Girr reveals novel inhibitors of Mycobacterium smegmatis growth

Author

Pollenz, Richard S, primary, Barnhill, Kaylee, additional, Biggs, Abbigail, additional, Bland, Jackson, additional, Carter, Victoria, additional, Chase, Michael, additional, Clark, Hayley, additional, Coleman, Caitlyn, additional, Daffner, Marshall, additional, Deam, Caitlyn, additional, Finocchiaro, Alyssa, additional, Franco, Vanessa, additional, Fuller, Thomas, additional, Pinera, Juan Gallardo, additional, Horne, Mae, additional, Howard, Zoe, additional, Kanahan, Olivia, additional, Miklaszewski, Christopher, additional, Miller, Sydney, additional, Morgan, Ryan, additional, Onalaja, Oluwatobi, additional, Otero, Louis, additional, Padhye, Shivani, additional, Rainey, Emily, additional, Rasul, Fareed, additional, Robichaux, Kobe, additional, Rodier, Alexandra, additional, Schlosser, Sydni, additional, Sciacchitano, Ava, additional, Stewart, Emma, additional, Thakkar, Rajvi, additional, and Heller, Danielle M, additional

Published
2024
Full Text
View/download PDF

19. Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional Analysis

Author

Menzies-Gow, Andrew, primary, Tran, Trung, additional, Stanley, Brooklyn, additional, Carter, Victoria, additional, Smolen, Josef, additional, Bourdin, Arnaud, additional, Fitzgerald, J, additional, Raine, Tim, additional, Chapaneri, Jatin, additional, Emmanuel, Benjamin, additional, Jackson, David, additional, and Price, David, additional

Published
2024
Full Text
View/download PDF

20. Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”

Author

Chen, Wenjia, primary, Tran, Trung N., additional, Sadatsafavi, Mohsen, additional, Murray, Ruth B., additional, Boon Wong, Nigel Chong, additional, Ali, Nasloon, additional, Ariti, Con, additional, Bulathsinhala, Lakmini, additional, Garcia Gil, Esther, additional, FitzGerald, J. Mark, additional, Alacqua, Marianna, additional, Al-Ahmad, Mona, additional, Altraja, Alan, additional, Al-Lehebi, Riyad, additional, Bhutani, Mohit, additional, Bjermer, Leif, additional, Bjerrum, Anne-Sofie, additional, Bourdin, Arnaud, additional, von Bülow, Anna, additional, Busby, John, additional, Canonica, Giorgio Walter, additional, Carter, Victoria, additional, Christoff, George C., additional, Cosio, Borja G., additional, Costello, Richard W., additional, Fonseca, João A., additional, Gibson, Peter G., additional, Yoo, Kwang Ha, additional, Heaney, Liam G., additional, Heffler, Enrico, additional, Hew, Mark, additional, Hilberg, Ole, additional, Hoyte, Flavia, additional, Iwanaga, Takashi, additional, Jackson, David J., additional, Jones, Rupert C., additional, Koh, Mariko Siyue, additional, Kuna, Piotr, additional, Larenas-Linnemann, Désirée, additional, Lehmann, Sverre, additional, Lehtimäki, Lauri, additional, Lyu, Juntao, additional, Mahboub, Bassam, additional, Maspero, Jorge, additional, Menzies-Gow, Andrew N., additional, Newell, Anthony, additional, Sirena, Concetta, additional, Papadopoulos, Nikolaos G., additional, Papaioannou, Andriana I., additional, Perez-de-Llano, Luis, additional, Perng (Steve), Diahn-Warng, additional, Peters, Matthew J., additional, Pfeffer, Paul E., additional, Porsbjerg, Celeste M., additional, Popov, Todor A., additional, Rhee, Chin Kook, additional, Salvi, Sundeep, additional, Taillé, Camille, additional, Taube, Christian, additional, Torres-Duque, Carlos A., additional, Ulrik, Charlotte, additional, Ra, Seung Won, additional, Wang, Eileen, additional, Wechsler, Michael E., additional, and Price, David B., additional

Published
2024
Full Text
View/download PDF

21. Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry

Author

Denton, Eve, Price, David B., Tran, Trung N., Canonica, G. Walter, Menzies-Gow, Andrew, FitzGerald, J. Mark, Sadatsafavi, Mohsen, Perez de Llano, Luis, Christoff, George, Quinton, Anna, Rhee, Chin Kook, Brusselle, Guy, Ulrik, Charlotte, Lugogo, Njira, Hore-Lacy, Fiona, Chaudhry, Isha, Bulathsinhala, Lakmini, Murray, Ruth B., Carter, Victoria A., and Hew, Mark

Published
2021
Full Text
View/download PDF

22. Potential Severe Asthma Hidden in UK Primary Care

Author

Ryan, Dermot, Heatley, Heath, Heaney, Liam G., Jackson, David J., Pfeffer, Paul E., Busby, John, Menzies-Gow, Andrew N., Jones, Rupert, Tran, Trung N., Al-Ahmad, Mona, Backer, Vibeke, Belhassen, Manon, Bosnic-Anticevich, Sinthia, Bourdin, Arnaud, Bulathsinhala, Lakmini, Carter, Victoria, Chaudhry, Isha, Eleangovan, Neva, FitzGerald, J. Mark, Gibson, Peter G., Hosseini, Naeimeh, Kaplan, Alan, Murray, Ruth B., Rhee, Chin Kook, Van Ganse, Eric, and Price, David B.

Published
2021
Full Text
View/download PDF

23. Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study

Author

Miravitlles, Marc, Esquinas, Cristina, Barrecheguren, Miriam, Nuñez, Alexa, Alcazar, Bernardino, García-Rivero, Juan Luis, Hueso, Karina, Roman-Rodríguez, Miguel, Sliwinski, Pawel, Iwan, Katarzyna, Kolakowski, Jacek, Rhee, Chin Kook, Ahn, Esther, Tan, Jessica, Laperre, Therese, Leng, Karen Tan Li, Chia, Nicole, How, Ong Thun, Shamsuddin, SyifaBinte, Gim, Sherine Lim Shu, Bee, Yap Chwee, Ya, Soh Rui, Tee, Augustine, Yan, Jun Jie, Hong, Samuel, Tan, William, Carter, Victoria, Hardaker, Latife, McLaughlin, Andrew, Gouder, Caroline, Costello, Richard W., Tan, Jessica H.Y., Lapperre, Therese Sophie, Kemppinen, Anu, Soler-Cataluña, Juan José, and Price, David B.

Published
2021
Full Text
View/download PDF

24. Evaluation of the innate immune responses to influenza and live-attenuated influenza vaccine infection in primary differentiated human nasal epithelial cells

Author

Forero, Adriana, Fenstermacher, Katherine, Wohlgemuth, Nicholas, Nishida, Andrew, Carter, Victoria, Smith, Elise A, Peng, Xinxia, Hayes, Melissa, Francis, Doreen, Treanor, John, Morrison, Juliet, Klein, Sabra L, Lane, Andrew, Katze, Michael G, and Pekosz, Andrew

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Vaccine Related, Clinical Research, Immunization, Infectious Diseases, Emerging Infectious Diseases, Biodefense, Prevention, Pneumonia & Influenza, Influenza, 2.2 Factors relating to the physical environment, Aetiology, 2.1 Biological and endogenous factors, Infection, Inflammatory and immune system, Good Health and Well Being, Animals, Antigen-Presenting Cells, Cell Line, Dogs, Epithelial Cells, Humans, Immunity, Innate, Influenza A Virus, H3N2 Subtype, Influenza Vaccines, Influenza, Human, Leukocytes, Mononuclear, Madin Darby Canine Kidney Cells, Nasal Mucosa, T-Lymphocytes, Vaccines, Attenuated, Influenza virus, Host response, Live-attenuated vaccine, Inflammation, Interferon, Epithelial cells, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Biomedical and clinical sciences, Health sciences
Abstract

The host innate immune response to influenza virus is a key determinant of pathogenic outcomes and long-term protective immune responses against subsequent exposures. Here, we present a direct contrast of the host responses in primary differentiated human nasal epithelial cell (hNEC) cultures following infection with either a seasonal H3N2 influenza virus (WT) or the antigenically-matched live-attenuated vaccine (LAIV) strain. Comparison of the transcriptional profiles obtained 24 and 36h post-infection showed that the magnitude of gene expression was greater in LAIV infected relative to that observed in WT infected hNEC cultures. Functional enrichment analysis revealed that the antiviral and inflammatory responses were largely driven by type III IFN induction in both WT and LAIV infected cells. However, the enrichment of biological pathways involved in the recruitment of mononuclear leukocytes, antigen-presenting cells, and T lymphocytes was uniquely observed in LAIV infected cells. These observations were reflective of the host innate immune responses observed in individuals acutely infected with influenza viruses. These findings indicate that cell-intrinsic type III IFN-mediated innate immune responses in the nasal epithelium are not only crucial for viral clearance and attenuation, but may also play an important role in the induction of protective immune responses with live-attenuated vaccines.

Published
2017

25. Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS

Author

Price,David, Henley,William, Cançado,José, Fabbri,Leonardo, Kerstjens,Huib, Papi,Alberto, Roche,Nicolas, Şen,Elif, Singh,Dave, Vogelmeier,Claus, Nudo,Elena, Carter,Victoria, Skinner,Derek, Vella,Rebecca, Soriano,Joan, Kots,Maxim, Georges,George, Price,David, Henley,William, Cançado,José, Fabbri,Leonardo, Kerstjens,Huib, Papi,Alberto, Roche,Nicolas, Şen,Elif, Singh,Dave, Vogelmeier,Claus, Nudo,Elena, Carter,Victoria, Skinner,Derek, Vella,Rebecca, Soriano,Joan, Kots,Maxim, and Georges,George

Abstract

David Price,1,2 William Henley,1,3 José Eduardo Delfini Cançado,4 Leonardo M Fabbri,5 Huib AM Kerstjens,6 Alberto Papi,7 Nicolas Roche,8 Elif Şen,9 Dave Singh,10 Claus F Vogelmeier,11 Elena Nudo,12 Victoria Carter,1 Derek Skinner,1 Rebecca Vella,1 Joan B Soriano,13 Maxim Kots,12 George Georges14 1Observational and Pragmatic Research Institute, Singapore; 2Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; 3Health Statistics Group, Department of Health and Community Sciences, University of Exeter Medical School, Exeter, UK; 4Santa Casa de São Paulo Medical School, São Paulo, Brazil; 5Respiratory Medicine, Department of Translational Medicine and for Romagna, University of Ferrara, Ferrara, Italy; 6Department of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, and Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands; 7Respiratory Medicine, University of Ferrara, Ferrara, Italy; 8Department of Respiratory Medicine, APHP-Centre University of Paris, Cochin Hospital and Institute (UMR1016), Paris, France; 9Department of Pulmonary Medicine, Ankara University School of Medicine, Ankara, Turkey; 10Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 11Department of Internal Medicine, Pulmonary and Critical Care Medicine, University of Marburg, Member of the German Centre for Lung Research (DZL), Marburg, Germany; 12Global Medical Affairs, Chiesi Farmaceutici, S.p.A, Parma, Italy; 13Respiratory Department, Hospital Universitario de La Princesa and Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain; 14Global Clinical Development, Chiesi Farmaceutici, S.p.A, Parma, ItalyCorrespondence: David Price, Observational and Pragmatic Research Institute, 22 Sin Ming Lane, #06-76, Midview City, 573969, Singapore, Tel +65 3105 1489, E

Published
2024

26. Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional Analysis

Author

Menzies-Gow,Andrew, Tran,Trung, Stanley,Brooklyn, Carter,Victoria, Smolen,Josef, Bourdin,Arnaud, Fitzgerald,J, Raine,Tim, Chapaneri,Jatin, Emmanuel,Benjamin, Jackson,David, Price,David, Menzies-Gow,Andrew, Tran,Trung, Stanley,Brooklyn, Carter,Victoria, Smolen,Josef, Bourdin,Arnaud, Fitzgerald,J, Raine,Tim, Chapaneri,Jatin, Emmanuel,Benjamin, Jackson,David, and Price,David

Abstract

Andrew N Menzies-Gow,1,2 Trung N Tran,3 Brooklyn Stanley,4 Victoria Ann Carter,4 Josef S Smolen,5 Arnaud Bourdin,6 J Mark Fitzgerald7 ,†Tim Raine,8 Jatin Chapaneri,2 Benjamin Emmanuel,3 David J Jackson,9,10 David B Price4,11 1Royal Brompton and Harefield Hospitals, Guys & St Thomas’ NHS Foundation Trust, London, UK; 2AstraZeneca, Cambridge, UK; 3AstraZeneca, Gaithersburg, MD, USA; 4Observational and Pragmatic Research Institute, Singapore; 5Medical University of Vienna, Vienna, Austria; 6Université de Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France; 7The University of British Columbia, Vancouver, British Columbia, Canada; 8Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge, UK; 9Guy’s Severe Asthma Centre, Guy’s & St Thomas’ NHS Trust, London, UK; 10School of Immunology & Microbial Sciences, King’s College London, London, UK; 11Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK†J. Mark Fitzgerald passed away on January 18, 2022Correspondence: David B Price, Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building-Foresterhill, Aberdeen, AB25 2ZD, UK, Tel +65 3105 1489, Email dprice@opri.sgPurpose: Associations between systemic glucocorticoid (SGC) exposure and risk for adverse outcomes have spurred a move toward steroid-sparing treatment strategies. Real-world changes in SGC exposure over time, after the introduction of steroid-sparing treatment strategies, reveal areas of successful risk mitigation as well as unmet needs.Patients and Methods: A population-based ecological study was performed from the Optimum Patient Care Research Database to describe SGC prescribing trends of steroid-sparing treatment strategies in primary care practices before and after licensure of biologics in the United Kingdom from 1990 to 2019. Each analysis year included patients aged ≥ 5

Published
2024

28. Healthcare Resource Utilization Associated with Intermittent Oral Corticosteroid Prescribing Patterns in Asthma.

Author

Tran, Trung N, Heatley, Heath, Bourdin, Arnaud, Menzies-Gow, Andrew, Jackson, David J, Maslova, Ekaterina, Chapaneri, Jatin, Henley, William, Carter, Victoria, Chan, Jeffrey Shi Kai, Ariti, Cono, Haughney, John, and Price, David

Subjects
LENGTH of stay in hospitals, HOSPITAL statistics, MEDICAL care costs, MEDICAL records, PRIMARY care
Abstract

Purpose: Oral corticosteroid (OCS) use for asthma is associated with considerable healthcare resource utilization (HCRU) and costs. However, no study has investigated this in relation to patterns of intermittent OCS prescription. Methods: This historical UK cohort study used primary care medical records, linked to Hospital Episode Statistics, from 2008 to 2019, of patients (≥ 4 years old) with asthma prescribed intermittent OCS. Patients were categorized by OCS prescribing pattern (one-off [single], less frequent [≥ 90-day gap] and frequent [< 90-day gap]) and matched 1:1 (by sex, age and index date) with people never prescribed OCS with/without asthma. HCRU (reported as episodes, except for length of hospital stay [days] and any prescription [records]) and associated costs were compared between intermittent OCS and non-OCS cohorts, and among intermittent OCS prescribing patterns. Results: Of 149,191 eligible patients, 50.3% had one-off, 27.4% less frequent, and 22.3% frequent intermittent OCS prescribing patterns. Annualized non-respiratory HCRU rates were greater in the intermittent OCS versus non-OCS cohorts for GP visits (5.93 vs 4.70 episodes, p < 0.0001), hospital admissions (0.24 vs 0.16 episodes, p < 0.0001), and length of stay (1.87 vs 1.58 days, p < 0.0001). In the intermittent OCS cohort, rates were highest in the frequent prescribing group for GP visits (7.49 episodes; p < 0.0001 vs one-off), length of stay (2.15 days; p < 0.0001) and any prescription including OCS (25.22 prescriptions; p < 0.0001). Mean per-patient non-respiratory related and all-cause HCRU-related costs were higher with intermittent OCS than no OCS (£ 3902 vs £ 2722 and £ 8623 vs £ 4929, respectively), as were mean annualized costs (£ 565 vs £ 313 and £ 1526 vs £ 634, respectively). A dose–response relationship existed; HCRU-related costs were highest in the frequent prescribing cohort (p < 0.0001). Conclusion: Intermittent OCS use and more frequent intermittent OCS prescription patterns were associated with increased HCRU and associated costs. Improved asthma management is needed to reduce reliance on intermittent OCS in primary care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry

Author

Wang, Eileen, Wechsler, Michael E., Tran, Trung N., Heaney, Liam G., Jones, Rupert C., Menzies-Gow, Andrew N., Busby, John, Jackson, David J., Pfeffer, Paul E., Rhee, Chin Kook, Cho, You Sook, Canonica, G. Walter, Heffler, Enrico, Gibson, Peter G., Hew, Mark, Peters, Matthew, Harvey, Erin S., Alacqua, Marianna, Zangrilli, James, Bulathsinhala, Lakmini, Carter, Victoria A., Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Murray, Ruth B., and Price, David B.

Published
2020
Full Text
View/download PDF

30. International Severe Asthma Registry: Mission Statement

Author

Canonica, G. Walter, Alacqua, Marianna, Altraja, Alan, Backer, Vibeke, Bel, Elisabeth, Bjermer, Leif, Bjornsdottir, Unnur, Bourdin, Arnaud, Brusselle, Guy G., Christoff, George C., Cosio, Borja G., Costello, Richard W., FitzGerald, J. Mark, Gibson, Peter G., Heaney, Liam G., Heffler, Enrico, Hew, Mark, Iwanaga, Takashi, Jones, Rupert C., Siyue, Mariko Koh, Rhee, Chin Kook, Lehmann, Sverre, Lehtimäki, Lauri A., Ludviksdottir, Dora, Maitland-van der Zee, Anke-Hilse, Menzies-Gow, Andrew N., Papadopoulos, Nikolaos G., Plaza, Vicente, Perez de Llano, Luis, Peters, Matthew, Porsbjerg, Celeste M., Sadatsafavi, Mohsen, Cho, You Sook, Tohda, Yuji, Tran, Trung N., Wang, Eileen, Zangrilli, James, Bulathsinhala, Lakmini, Carter, Victoria A., Chaudhry, Isha, Eleangovan, Neva, Hosseini, Naeimeh, Le, Thao L., Murray, Ruth B., Price, Chris A., and Price, David B.

Published
2020
Full Text
View/download PDF

32. Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS

Author

Price, David, primary, Henley, William, additional, Cançado, José, additional, Fabbri, Leonardo, additional, Kerstjens, Huib, additional, Papi, Alberto, additional, Roche, Nicolas, additional, Şen, Elif, additional, Singh, Dave, additional, Vogelmeier, Claus, additional, Nudo, Elena, additional, Carter, Victoria, additional, Skinner, Derek, additional, Vella, Rebecca, additional, Soriano, Joan, additional, Kots, Maxim, additional, and Georges, George, additional

Published
2024
Full Text
View/download PDF

33. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma

Author

Perez-de-Llano, Luis, primary, Scelo, Ghislaine, additional, Canonica, G. Walter, additional, Chen, Wenjia, additional, Henley, William, additional, Larenas-Linnemann, Désirée, additional, Peters, Matthesadatw J, additional, Pfeffer, Paul E., additional, Tran, Trung N., additional, Ulrik, Charlotte Suppli, additional, Popov, Todor A., additional, Sadatsafavi, Mohsen, additional, Hew, Mark, additional, Maspero, Jorge, additional, Gibson, Peter G., additional, Christoff, George C., additional, Fitzgerald, J. Mark, additional, Torres-Duque, Carlos A., additional, Porsbjerg, Celeste M., additional, Papadopoulos, Nikolaos G., additional, Papaioannou, Andriana I., additional, Heffler, Enrico, additional, Iwanaga, Takashi, additional, Al-Ahmad, Mona, additional, Kuna, Piotr, additional, Fonseca, João A, additional, Al-Lehebi, Riyad, additional, Rhee, Chin Kook, additional, Koh, Mariko Siyue, additional, Cosio, Borja G., additional, Perng (Steve), Diahn-Warng, additional, Mahboub, Bassam, additional, Menzies-Gow, Andrew N., additional, Jackson, David J., additional, Busby, John, additional, Heaney, Liam G., additional, Patel, Pujan H, additional, Wang, Eileen, additional, Wechsler, Michael E., additional, Altraja, Alan, additional, Lehtimäki, Lauri, additional, Bourdin, Arnaud, additional, Bjermer, Leif, additional, Bulathsinhala, Lakmini, additional, Carter, Victoria, additional, Murray, Ruth, additional, Beastall, Aaron, additional, Denton, Eve, additional, and Price, David B., additional

Published
2023
Full Text
View/download PDF

34. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma

Author

Wechsler, Michael E, primary, Scelo, Ghislaine, additional, Larenas-Linnemann, Désirée E. S., additional, Torres-Duque, Carlos A., additional, Maspero, Jorge, additional, Tran, Trung N., additional, Murray, Ruth B., additional, Martin, Neil, additional, Menzies-Gow, Andrew N., additional, Hew, Mark, additional, Peters, Matthew J, additional, Gibson, Peter G, additional, Christoff, George C., additional, Popov, Todor A., additional, Côté, Andréanne, additional, Bergeron, Celine, additional, Dorscheid, Delbert, additional, FitzGerald, J Mark, additional, Chapman, Kenneth R, additional, Boulet, Louis Philippe, additional, Bhutani, Mohit, additional, Sadatsafavi, Mohsen, additional, Jiménez-Maldonado, Libardo, additional, Duran-Silva, Mauricio, additional, Rodriguez, Bellanid, additional, Celis-Preciado, Carlos Andres, additional, Cano-Rosales, Diana Jimena, additional, Solarte, Ivan, additional, Fernandez- Sanchez, Maria Jose, additional, Parada-Tovar, Patricia, additional, von Bülow, Anna, additional, Bjerrum, Anne Sofie, additional, Ulrik, Charlotte S, additional, Assing, Karin Dahl, additional, Rasmussen, Linda Makowska, additional, Hansen, Susanne, additional, Altraja, Alan, additional, Bourdin, Arnaud, additional, Taille, Camille, additional, Charriot, Jeremy, additional, Roche, Nicolas, additional, Papaioannou, Andriana I, additional, Kostikas, Konstantinos, additional, Papadopoulos, Nikolaos G., additional, Salvi, Sundeep, additional, Long, Deirdre, additional, Mitchell, Patrick D, additional, Costello, Richard, additional, Sirena, Concetta, additional, Cardini, Cristina, additional, Heffler, Enrico, additional, Puggioni, Francesca, additional, Canonica, Giorgio Walter, additional, Guida, Giuseppe, additional, Iwanaga, Takashi, additional, Al-Ahmad, Mona, additional, García, Ulises, additional, Kuna, Piotr, additional, Fonseca, João A., additional, Al-Lehebi, Riyad, additional, Koh, Mariko S., additional, Rhee, Chin Kook, additional, Cosio, Borja G, additional, Perez de Llano, Luis, additional, Perng, Diahn-Warng, additional, Huang, Erick Wan-Chun, additional, Wang, Hao-Chien, additional, Tsai, Ming-Ju, additional, Mahboub, Bassam, additional, Salameh, Laila Ibraheem Jaber, additional, Jackson, David J., additional, Busby, John, additional, Heaney, Liam G, additional, Pfeffer, Paul E., additional, Goddard, Amanda Grippen, additional, Wang, Eileen, additional, Hoyte, Flavia C. L., additional, Chapman, Nicholas M, additional, Katial, Rohit, additional, Carter, Victoria, additional, Bulathsinhala, Lakmini, additional, Eleangovan, Neva, additional, Ariti, Con, additional, Lyu, Juntao, additional, Porsbjerg, Celeste, additional, and Price, David B., additional

Published
2023
Full Text
View/download PDF

40. Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study

Author

Bulathsinhala, Lakmini, Eleangovan, Nevaashni, Heaney, Liam G., Menzies-Gow, Andrew, Gibson, Peter G., Peters, Matthew, Hew, Mark, van Boven, Job F.M., Lehtimäki, Lauri, van Ganse, Eric, Belhassen, Manon, Harvey, Erin S., Perez de Llano, Luis, Maitland-van der Zee, Anke H., Papadopoulos, Nikolaos G., FitzGerald, J. Mark, Porsbjerg, Celeste, Canonica, G. Walter, Backer, Vibeke, Rhee, Chin Kook, Verhamme, Katia M.C., Buhl, Roland, Cosio, Borja G., Carter, Victoria, Price, Chris, Le, Thao, Stagno d’Alcontres, Martina, Gopalan, Gokul, Tran, Trung N., and Price, David

Published
2019
Full Text
View/download PDF

41. The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia.

Author

Price, David, Jenkins, Christine, Hancock, Kerry, Vella, Rebecca, Heraud, Florian, Le Cheng, Porsche, Murray, Ruth, Beekman, Maarten, Bosnic-Anticevich, Sinthia, Botini, Fabio, Carter, Victoria, Catanzariti, Angelina, Doan, Joe, Fletton, Kirsty, Kichkin, Ata, Le, Thao, Le Lievre, Chantal, Lau, Chi Ming, Novic, Dominique, and Pakos, John

Abstract

Introduction: In Australia, short-acting β2-agonists (SABA) are available both over the counter (OTC) and on prescription. This ease of access may impact SABA use in the Australian population. Our aim was to assess patterns and outcome associations of prescribed, acquired OTC and reported use of SABA by Australians with asthma. Methods: This was a cross-sectional study, using data derived from primary care electronic medical records (EMRs) and patient completed questionnaires within Optimum Patient Care Research Database Australia (OPCRDA). A total of 720 individuals aged ≥ 12 years with an asthma diagnosis in their EMRs and receiving asthma therapy were included. The annual number of SABA inhalers authorised on prescription, acquired OTC and reported, and the association with self-reported exacerbations and asthma control were investigated. Results: 92.9% (n = 380/409) of individuals issued with SABA prescription were authorised ≥ 3 inhalers annually, although this differed from self-reported usage. Of individuals reporting SABA use (n = 546) in the last 12 months, 37.0% reported using ≥ 3 inhalers. These patients who reported SABA overuse experienced 2.52 (95% confidence interval [CI] 1.73–3.70) times more severe exacerbations and were 4.51 times (95% CI 3.13–6.55) more likely to have poor asthma control than those who reported using 1–2 SABA inhalers. Patients who did not receive SABA on prescription (43.2%; n = 311/720) also experienced 2.71 (95% CI 1.07–7.26) times more severe exacerbations than those prescribed 1–2 inhalers. Of these patients, 38.9% reported using OTC SABA and other prescription medications, 26.4% reported using SABA OTC as their only asthma medication, 13.2% were prescribed other therapies but not SABA OTC and 14.5% were not using any medication. Conclusion: Both self-reported SABA overuse and zero SABA prescriptions were associated with poor asthma outcomes. The disconnect between prescribing authorisation, OTC availability and actual use, make it difficult for clinicians to quantify SABA use. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Clinical remission following biologic initiation in severe asthma: results of the International Severe Asthma Registry (ISAR)

Author

Scelo, Ghislaine, primary, Tran, Trung N., additional, Le, Tham T., additional, Faregås, Malin, additional, Martin, Neil, additional, Menzies-Gow, Andrew N., additional, Eileen, Wang, additional, Wechsler, Michael, additional, Canonica, Giorgio Walter, additional, Heffler, Enrico, additional, Heaney, Liam G., additional, Jackson, David J., additional, Pfeffer, Paul E, additional, Busby, John, additional, Porsbjerg, Celeste M., additional, Hew, Mark, additional, Peters, Matthew, additional, Gibson, Peter G., additional, Al-Ahmad, Mona, additional, Bergeron, Celine, additional, Sadatsafavi, Mohsen, additional, Perez-De-Llano, Luis, additional, Cosio, Borja G, additional, Kuna, Piotr, additional, Perng, Diahn-Warng, additional, Iwanaga, Takashi, additional, Torres-Duque, Carlos A., additional, Larenas-Linnemann, Désirée, additional, Mahboub, Bassam, additional, Al-Lehebi, Riyad, additional, Fonseca, João A., additional, Rhee, Chin Kook, additional, Máspero, Jorge, additional, Siyue, Mariko Koh, additional, Christoff, George C, additional, Popov, Todor A., additional, Kwiatek, Justin, additional, Carter, Victoria, additional, Goh, Celine, additional, Bulathsinhala, Lakmini, additional, Beastall, Aaron, additional, and Price, David, additional

Published
2023
Full Text
View/download PDF

43. Identifying opportunities for earlier diagnosis of high-risk COPD patients in Australia: an observational study

Author

Dickens, Andrew, primary, Jenkins, Christine, additional, Evans, Alexander, additional, Hancock, Kerry, additional, Sharma, Anita, additional, Cochrane, Belinda, additional, Leong, Paul, additional, Ko, Brian, additional, Heraud, Florian, additional, Le Cheng, Porsche, additional, Roussos, Alexander, additional, Bosnic-Anticevich, Sinthia, additional, Botini, Fabio, additional, Carter, Victoria, additional, Catanzariti, Angelina, additional, Ghisla, Clare, additional, Le, Thao, additional, Le Lievre, Chantal, additional, Murray, Ruth, additional, Ranasinghe, Kanchanamla, additional, Stewart, Deb, additional, Melle, Marije Van, additional, Vella, Rebecca, additional, Wiseman, Russell, additional, and Price, David, additional

Published
2023
Full Text
View/download PDF

44. Real world biologic treatment response in severe asthma: an analysis of the International Severe Asthma Registry (ISAR)

Author

Le, Tham T., primary, Scelo, Ghislaine, additional, Tran, Trung N.., additional, Faregås, Malin, additional, Martin, Neil, additional, Menzies-Gow, Andrew N., additional, Eileen, Wang, additional, Wechsler, Michael, additional, Canonica, Giorgio Walter, additional, Heffler, Enrico, additional, Heaney, Liam G., additional, Jackson, David J., additional, Pfeffer, Paul E., additional, Busby, John, additional, Porsbjerg, Celeste M., additional, Hew, Mark, additional, Peters, Matthew, additional, Gibson, Peter G., additional, Al-Ahmad, Mona, additional, Bergeron, Celine, additional, Sadatsafavi, Mohsen, additional, Perez-De-Llano, Luis, additional, Cosio, Borja G., additional, Kuna, Piotr, additional, Perng, Diahn-Warng, additional, Iwanaga, Takashi, additional, Torres-Duque, Carlos A., additional, Larenas-Linnemann, Désirée, additional, Mahboub, Bassam, additional, Papadopoulos, Nikolaos G., additional, Al-Lehebi, Riyad, additional, Fonseca, João A., additional, Rhee, Chin Kook, additional, Máspero, Jorge, additional, Siyue, Mariko Koh, additional, Christoff, George C., additional, Popov, Todor A., additional, Kwiatek, Justin, additional, Carter, Victoria, additional, Goh, Celine, additional, Bulathsinhala, Lakmini, additional, Beastall, Aaron, additional, and Price, David, additional

Published
2023
Full Text
View/download PDF

46. Characteristics associated with clinical remission in patients with severe asthma who initiate biologics

Author

Pérez De Llano, Luis, primary, Scelo, Ghislaine, additional, Tran, Trung N, additional, T. Le, Tham, additional, Martin, Neil, additional, Fagerås, Malin, additional, Menzies-Gow, Andrew N., additional, Wang, Eileen, additional, E. Wechsler, Michael, additional, Canonica, Giorgio Walter, additional, Heffler, Enrico, additional, Heaney, Liam G., additional, Jackson, David J., additional, Pfeffer, Paul E., additional, Busby, John, additional, Porsbjerg, Celeste M., additional, Hew, Mark, additional, Peters, Matthew, additional, Gibson, Peter G., additional, Al-Ahmad, Mona, additional, Bergeron, Celine, additional, Sadatsafavi, Mohsen, additional, Cosio, Borja G., additional, Kuna, Piotr, additional, Perng, Diahn-Warng, additional, Iwanaga, Takashi, additional, Torres-Duque, Carlos A., additional, Larenas-Linnemann, Désirée, additional, Mahboub, Bassam, additional, Papadopoulos, Nikolaos G., additional, Al-Lehebi, Riyad, additional, Fonseca, João A., additional, Kook Rhee, Chin, additional, Máspero, Jorge, additional, Koh, Mariko Siyue, additional, Christoff, George C., additional, Popov, Todor A., additional, Kwiatek, Justin, additional, Carter, Victoria, additional, Goh, Celine, additional, Bulathsinhala, Lakmini, additional, Beastall, Aaron, additional, and Price, David, additional

Published
2023
Full Text
View/download PDF

47. A genome-wide cytotoxicity screen of Cluster F1 mycobacteriophage Girr reveals novel inhibitors ofMycobacterium smegmatisgrowth

Author

Pollenz, Richard S, primary, Barhnhill, Kaylee, additional, Biggs, Abbigail, additional, Bland, Jackson, additional, Carter, Victoria, additional, Chase, Michael, additional, Clark, Hayley, additional, Coleman, Caitlyn, additional, Daffner, Marshall, additional, Deam, Caitlyn, additional, Finocchiaro, Alyssa, additional, Franco, Vanessa, additional, Fuller, Thomas, additional, Pinera, Juan Gallardo, additional, Horne, Mae, additional, Howard, Zoe, additional, Kanahan, Olivia, additional, Miklaszewski, Chris, additional, Miller, Sydney, additional, Morgan, Ryan, additional, Onalaja, Oluwatobi, additional, Otero, Louis, additional, Padhye, Shivani, additional, Rainey, Emily, additional, Rasul, Fareed, additional, Robichaux, Kobe, additional, Rodier, Alexandra, additional, Schlosser, Sydni, additional, Sciacchitano, Ava, additional, Stewart, Emma, additional, Thakkar, Rajvi, additional, and Heller, Danielle, additional

Published
2023
Full Text
View/download PDF

50. Disparities in Tdap Vaccination and Vaccine Information Needs Among Pregnant Women in the United States

Author

Kriss, Jennifer L., Albert, Alison P., Carter, Victoria M., Jiles, Angela J., Liang, Jennifer L., Mullen, Jennifer, and Rodriguez, Leslie

Subjects
Immunization -- Standards, Diphtheria-tetanus-pertussis vaccines -- Usage -- Research, Pregnant women -- Health aspects -- Research, Health care industry
Abstract

Objectives The Advisory Committee on Immunization Practices (ACIP) and the American College of Obstetricians and Gynecologists (ACOG) recommend that pregnant women receive the Tdap vaccine during every pregnancy. The objectives of this paper are to evaluate disparities in Tdap vaccination among pregnant women in the U.S., and to assess whether race/ethnicity and other characteristics are associated with factors that inform pregnant women's decisions about Tdap vaccination. Methods We conducted a nationwide cross-sectional web-based survey of pregnant women in the U.S. during June-July 2014. The primary outcome was self-reported vaccination status with Tdap during pregnancy, categorized as vaccinated, unvaccinated with intent to be vaccinated during the current pregnancy, and unvaccinated with no intent to be vaccinated during the current pregnancy. Secondary outcomes included factors that influenced women's decisions about vaccination and information needs. We used multivariable logistic regression models to estimate odds ratios for associations between race/ethnicity and the outcomes. Results Among pregnant women who completed the survey, 41% (95% CI 36-45%) reported that they had received Tdap during the current pregnancy. Among those women in the third trimester at the time of survey, 52% (95% CI 43-60%) had received Tdap during the current pregnancy. Hispanic women had higher Tdap vaccination than white women and black women (53%, p < 0.05, compared with 38 and 36%, respectively). In logistic regression models adjusting for maternal age, geographic region, education, and income, Hispanic women were more likely to have been vaccinated with Tdap compared with white women (aOR 2.29, 95% CI 1.20-4.37). Higher income and residing in the western U.S. were also independently associated with Tdap vaccination during pregnancy. Twenty-six percent of surveyed women had not been vaccinated with Tdap yet but intended to receive the vaccine during the current pregnancy; this proportion did not differ significantly by race/ethnicity. The most common factor that influenced women to get vaccinated was a health care provider (HCP) recommendation. The most common reason for not getting vaccinated was a concern about safety of the vaccine. Conclusions This study found that some disparities exist in Tdap vaccination among pregnant women in the U.S., and HCPs have an important role in providing information and recommendations about the maternal Tdap recommendation to pregnant women so they can make informed vaccination decisions., Author(s): Jennifer L. Kriss [sup.1] , Alison P. Albert [sup.2] , Victoria M. Carter [sup.3] , Angela J. Jiles [sup.2] , Jennifer L. Liang [sup.2] , Jennifer Mullen [sup.3] , [...]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results